Affimed N.V. announced that management will present and host one-on-one meetings at the following investor conferences during the month of February 2022.
HEIDELBERG, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following investor conferences during the month of February 2022.
11th SVB Leerink 2022 Global Healthcare Conference (February 14 - 18, 2022)
Date: Wednesday, February 16, 2022
Presentation Time: 11:20 a.m. EST / 17:20 CET
Webcast: https://www.affimed.com/investors/webcasts-and-corporate-presentation/
Location: Virtual
Citi’s 2022 Virtual Immuno-Oncology Summit (February 17, 2022)
Date: Thursday, February 17, 2022
Presentation Time: 2:30 p.m. EST / 20:30 CET
Webcast: https://www.affimed.com/investors/webcasts-and-corporate-presentation/
Location: Virtual
For more information on the conferences or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: https://www.affimed.com.
Affimed Investor Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
